Retatrutide
Also known as: LY3437943
Brand names: LY3437943
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28.7% of body weight in 48-week trials. The peptide works by simultaneously activating three metabolic pathways: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This multi-pronged approach appears to produce superior weight loss compared to existing FDA-approved medications. In the Phase 3 TRIUMPH-4 trial (December 2025), patients on the 12mg dose lost an average of 28.7% of body weight over 68 weeks, with 39.4% of participants achieving 30% or greater weight loss. An NDA submission to the FDA is expected in late 2026.
Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) |
| Frequency | Weekly |
Common Side Effects
Serious Side Effects
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy
Evidence Quality
Clinical Trial Phase
Phase 3
Average Weight Loss in Trials
28.7%
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| Retatrutide | $1200 - $1500/mo | Phase 3 (NDA expected late 2026) |
| Semaglutide | $1000 - $1400/mo | FDA Approved |
| Tirzepatide | $1100 - $1100/mo | FDA Approved |
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.